Alector stock
ALECNASDAQAlector, Inc., HealthcareISIN US0144421072
71Score 71 out of 100, Strong
Price and trend
82 / 100
Price history
+83% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 19% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 68).
The price is 9.9% below its 52-week high. Largest decline in 8 years: 98% (July 2021 to April 2025).
Chart figures for advanced users
- SMA 50$2.07
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$2.05
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)68
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.14
- The lowest closing price of the last twelve months.
- Resistance$2.72
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Alector, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $364.75M, is number 268 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $21.05M (down 79.1% year on year) and a loss of $142.93M.
- For fiscal 2026, analysts expect on average revenue of $75.63M (up 259.4%) and adjusted earnings per share of −$0.31.
Show more
- MEQIRI Score 71 out of 100 (Strong): rank 112 of 714 in Healthcare, median 53.
- Our model puts fair value at $7.93, with the price 67% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 67% below the fair value of $7.93.Valuation 100
- More cash than debtCash $138.7M, financial debt $21M.Stability 67
- High marginNet margin 23.9% over the last 12 months, Biotechnology median −93.3%.Profitability 91
Weaknesses
- DilutionShare count up 32% since 2020.Capital allocation 47
- Volatile share priceVolatility 84% a year over the last 12 months.Stability 67
- Negative free cash flowFree cash flow −$150.02M over the last 12 months.Fundamentals 35
Its standout strengths are valuation and momentum, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
One-off effect in revenue
In the quarter to 30 Sep 2026, revenue of $162.87M was about 33 times the usual level. P/E, margin, growth and score for the last twelve months depend on it.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- weak fundamentals
- price up very strongly over the past year
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $5.28 and expensive above $15.85 (uncertainty very high, based on the price swings of the past year).
Valuation metrics
From earnings times the industry P/E (21.3) alone; there are no viable cash flows for the cash-flow model.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 82.9% on the twelve months before. Revenue has grown strongly since 2016, at around 55% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 54%, operating −693%, net −679%. Last 12 months: net 24%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 5 Nov 2026EPS reported $1.11 (expected −$0.23)above expectations
Analyst estimates
Earnings estimates have barely changed since 8 Nov 2026.
- Earnings per share
- −$0.310.0%
- Revenue
- $75.63M0.0%
- Earnings per share
- −$0.840.0%
- Revenue
- $17.46M0.0%
MEQIRI has stored the estimates since 8 Nov 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $296,087 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Alector
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 71
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- CorMedixCRMD $413.1M59
- X4 PharmaceuticalsXFOR $408.67M37
- ARS PharmaceuticalsSPRY $397.09M33
- NeurogeneNGNE $396.64M34
- ProKidneyPROK $379.97M27
- C4 TherapeuticsCCCC $379.51M35
- AltimmuneALT $375.42M25
- Fennec PharmaceuticalsFENC $373.11M52
ETFs that hold Alector
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.00% | 0.30% | €4.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 9 Nov 2026, previously Neutral
- Valuation signal Undervalued since 9 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.